Human Identification Market worth $804.0 Million by 2018, According to a New Study on ASDReports

Thursday 22 May 2014, Amsterdam

The “Human Identification Market by Technology (Next Generation Sequencing, Rapid DNA Analysis, Capillary Electrophoresis, PCR), Application (Forensics, Paternity Testing), DNA Amplification, Quantification, Extraction, Services, & Software - Forecast to 2018”, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Human Identification market along with the estimates and forecasts of the revenue and share analysis.

The global Human Identification market was valued at an estimated $419.4 million in 2013 and is expected to reach $804.0 million by 2018, growing at a CAGR of 13.9% between 2013 and 2018.

The report segments this market based on technology, application, products and services, and geography. Among various technologies, the capillary electrophoresis commanded the largest share in 2013, while next generation sequencing (NGS) is forecasted to be the fastest-growing segment in the human identification market. Factors such as rising awareness regarding new technologies for the DNA analysis, government support in the form of funding, and the need to reduce time and cost associated with DNA analysis are driving the growth of human identification market. Furthermore, owing to continuous advancements in technology, new and innovative products are being launched in the market which is another major factor providing impetus for growth of the market.

Based on geography, the global human identification market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America accounted for the largest share of the market in 2013. This large share of the North American region can be attributed various factors including expansion of the U.S. national DNA database and government support in the form of grants and funds.

The prominent players in the human identification market are Thermo Fisher Scientific, Inc. (U.S.), Promega Corporation (U.S.), QIAGEN N.V. (The Netherlands), and Illumina (U.S.).